PANDEY NIVESH • MUTUAL FUND RESEARCH • 17 NOVEMBER 2026
New NFOs are arriving. Read the strategy—not just the ₹10 NAV.
A launch calendar is a starting point for research, not a buy list.
Research date: 17 November 2026. This is a selected snapshot of offers reported open around this date. Tap any scheme name to open its research note. NFO dates, minimums and scheme terms can change; confirm the latest SID, KIM and AMC addenda before applying.
Selected offers reported open
| Scheme name — tap for analysis | Category / focus | NFO window | Min. amount |
|---|---|---|---|
| Kotak Nifty Pharma Index Fund | Pharma index | 16–30 Nov | ₹1,000 |
| Invesco India Nifty Metal Index Fund | Metal index | 16–30 Nov | ₹100 |
| Invesco India BSE Top 10 Banks ETF | Banking ETF | 16–30 Nov | ₹5,000 |
| SBI BSE India Defence ETF FoF | Defence ETF FoF | 16–30 Nov | ₹5,000 |
| WhiteOak Capital Contra Fund | Contra strategy | 16–30 Nov | ₹500 |
| Abakkus Dynamic Asset Allocation Fund | Dynamic asset allocation | 16–30 Nov | ₹500 |
| HDFC Charity Fund for Cancer Cure (Feb 2030) | Close-ended debt | 16–30 Nov | ₹50,000 |
How to read the research notes
Each note separates confirmed scheme facts from analysis and unavailable data. A new NFO does not have its own historical performance. Therefore alpha, beta, Sharpe ratio, information ratio and rolling-return consistency cannot honestly be calculated for the new scheme at launch. For passive funds, the relevant checks are index construction, constituent weights, concentration, tracking difference, tracking error and TER. For active funds, compare the mandate, portfolio after disclosure, manager process, costs and relevant peer category once a live record exists.
Kotak Nifty Pharma Index Fund
Mandate: Open-ended passive equity scheme tracking the Nifty Pharma Index; benchmark: Nifty Pharma TRI. The index provides concentrated exposure to listed pharmaceutical companies, not the whole healthcare ecosystem. Sector contribution should be read from the latest official index factsheet, including each constituent’s weight; the fund’s actual holdings and weights may differ slightly because of cash and tracking constraints.
What to measure: top-5/top-10 constituent concentration, constituent weights, API/formulation/CRAMS business mix where disclosed, export and US-regulatory exposure, valuation dispersion, index volatility, tracking error, tracking difference and TER. Pharma index sector exposure is effectively 100% pharma-index exposure; it is not a diversified large-cap core holding.
Performance metrics: fund alpha/beta/Sharpe/Sortino are not available before the scheme builds a return history. Use the Nifty Pharma TRI’s historical risk/return only as index context, not as the new fund’s track record. Kotak AMC official site and scheme documents.
Invesco India Nifty Metal Index Fund
Mandate: Passive equity scheme tracking Nifty Metal TRI. This is a cyclical sector exposure influenced by domestic infrastructure and capex, global commodity prices, China demand/supply, energy costs, trade policy and currency movements.
What to measure: top constituent weights, steel/aluminium/mining diversification, commodity and global-demand sensitivity, leverage/capex cycle of major holdings, index concentration, tracking error, tracking difference and TER. A sector fund can fall sharply during a commodity down-cycle; do not treat it as a diversified equity replacement.
Performance metrics: no fund-level alpha, beta, Sharpe or rolling returns exist at launch. Compare the index TRI’s dated history with Nifty 50 TRI and relevant sector peers, clearly labelled as index history, not fund performance. Invesco scheme details.
Invesco India BSE Top 10 Banks ETF
Mandate: ETF tracking the BSE Top 10 Banks Index, covering ten leading listed banks across public and private sectors. The underlying index, not a discretionary stock-picking portfolio, determines exposure.
What to measure: bank-wise weights, public/private bank split, top-3 concentration, loan growth, deposit growth, CASA, net interest margin, gross/net NPA, credit cost, capital adequacy and valuation multiples (P/B and ROE). ETF-specific checks include TER, tracking difference, tracking error, exchange liquidity, bid–ask spread and premium/discount to iNAV.
Performance metrics: no ETF alpha/beta/Sharpe history exists before launch. Use BSE Top 10 Banks TRI historical data as benchmark context only. Invesco scheme details.
SBI BSE India Defence ETF FoF
Mandate: Fund of Funds investing in SBI BSE India Defence ETF; benchmark reported as BSE India Defence TRI. This creates defence-theme exposure through an underlying ETF and therefore adds a fund-of-fund layer.
What to measure: underlying ETF constituents and weights, defence-platform versus aerospace/electronics/shipbuilding mix, order-book quality, execution and working-capital risk of underlying companies, government procurement dependence, export exposure, valuation and concentration. Also review both layers’ costs, underlying ETF tracking difference and FoF-level expenses.
Performance metrics: the FoF has no own historical alpha/beta/Sharpe/rolling returns at launch. Do not substitute the underlying index’s past returns for the new FoF’s record. SBI Mutual Fund official site.
WhiteOak Capital Contra Fund
Mandate: Active contra-style equity strategy. A contra fund typically seeks opportunities where market prices or sentiment are out of line with the manager’s assessment of long-term fundamentals; the exact investment universe, limits and benchmark must be confirmed in the current SID/KIM.
What to measure after portfolio disclosure: sector and market-cap contribution, top-10 holdings, active share, portfolio overlap with diversified equity peers, valuation versus growth, cash levels, turnover, drawdown, downside capture and benchmark-relative rolling returns. Compare against the benchmark and contra/value peers over matching periods.
Performance metrics: alpha, beta, Sharpe, Sortino and information ratio are not available for this newly launched scheme at NFO stage. Manager/AMC track record is not the same as this scheme’s performance. WhiteOak Capital AMC.
Abakkus Dynamic Asset Allocation Fund
Mandate: Dynamic allocation between equity and debt as defined by the scheme document. The model, allocation bands, hedging approach, rebalancing triggers and taxation classification must be checked in the SID/KIM rather than inferred from the fund name.
What to measure: gross and net equity exposure, hedged/unhedged exposure, debt duration and credit quality, asset-allocation range, cash, portfolio yield, equity valuation inputs, rebalancing discipline, downside capture, drawdown and total expense ratio. Compare with the scheme’s stated benchmark and dynamic-allocation peers only after matching risk and tax structure.
Performance metrics: no scheme alpha/beta/Sharpe/Sortino/rolling-return history at launch. A back-tested model, if published, is not actual investor performance. Abakkus AMC official site and SID.
HDFC Charity Fund for Cancer Cure (Feb 2030)
Mandate: Close-ended debt-oriented scheme with a defined maturity and an IDCW-linked charitable contribution feature described in its scheme documents. HDFC AMC reports a Moderate riskometer; the SID specifies a minimum NFO application of ₹50,000 and an NFO period of 16–30 November 2026. Read the exact IDCW donation mechanism, tenure, maturity date, listing/liquidity terms, taxation and all charges in the SID/KIM.
What to measure: portfolio credit quality, sovereign/SDL/corporate allocation, modified duration, Macaulay duration, yield-to-maturity, average maturity, issuer concentration, interest-rate sensitivity, liquidity and expense ratio. This is not an equity sector fund; equity alpha/beta and stock-sector contribution are not applicable.
Performance metrics: no scheme-level historical Sharpe/alpha/beta or realised return exists at launch. Evaluate debt risks and cash-flow/maturity structure, not equity metrics. HDFC AMC official NFO page · HDFC SID.
Measurement dashboard — what we will track
- Portfolio: sector contribution, stock/issuer weights, top-5/top-10 concentration, market-cap mix, active share and portfolio overlap where applicable.
- Risk: standard deviation, beta, maximum drawdown, downside capture, Sharpe, Sortino and tracking error; only when a meaningful return history exists.
- Performance: benchmark-relative returns, rolling 1/3/5-year returns, alpha and information ratio; use common dates and appropriate benchmarks, and label index/back-test data separately.
- Costs and execution: TER, exit load, tracking difference, ETF spread/liquidity, turnover and tax structure.
- Business fundamentals: for sector holdings, relevant sector-specific measures such as NIM/NPA for banks, commodity cycle and leverage for metals, regulatory/export mix for pharma, and order book/execution for defence.
Important data discipline: Before allotment, many schemes do not yet have a live portfolio or daily NAV history. We will show “Not yet available” rather than invent sector weights, constituent names, alpha, beta or risk statistics. Once monthly portfolios and NAV history are published, the research note can be expanded with measured figures, dated source links and peer comparisons.
Upcoming offers reported after this date
- Nippon India CRISIL-IBX SDL June 2037 Index Fund: reported 18–26 November 2026.
- Bajaj Finserv Business Cycle Fund: reported 20 November–4 December 2026.
- Other launches are subject to latest AMC and AMFI updates.
Important: ₹10 NAV does not mean cheap
An NFO’s initial offer price is not a discount or a measure of value. A new scheme has no long-term performance history of its own. Evaluate its strategy, costs, risk, benchmark and role in a diversified portfolio.
Sources: Invesco launch release; Invesco Metal scheme page; Invesco Banks ETF page; HDFC AMC NFO page; HDFC SID; Abakkus SID; AMFI. Dates and terms must be rechecked against current official documents before investing.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. This article is for education and information, not investment advice or a recommendation to subscribe to any NFO.

